Disclaimer for the US market

The products and information provided on this website are intended for healthcare professionals. These products are not for sale or distribution in the United States and statements made regarding these products have not been evaluated by the U.S. Food and Drug Administration (FDA). The efficacy of these products has not been confirmed by FDA-approved research and these products are therefore not intended to diagnose, treat, cure or prevent any disease. All information presented here is for general information purposes only and not meant as a substitute for or alternative to advice from healthcare practitioners. The Federal Food, Drug and Cosmetic Act requires this notice.

Neither the Company nor its representatives is providing any medical advice, and none should be inferred, from any ideas, suggestions, testimonials or other information set forth on this website or in other Company materials or provided over the phone, in the mail, in product packaging, or in email correspondence. This website may contain links to third-party websites. The Company provides these links as a convenience only and does not endorse any of these sites. The Company is not responsible for the content of, and does not make any representations regarding the materials on, such linked third-party websites. If you decide to access or rely on information at linked third-party website, you do so at our own risk. Our terms and conditions, including disclaimers, are more fully set forth in our Terms of Use, Privacy Policy and Terms of Online Sales.

Focus Meeting Heart in Münster: CARL scores with a lunch symposium

A lunch symposium on “CARL. Recap – Latest clinical experience reports and results from one year of CARL” attracted a large and interested audience at this year’s Focus Meeting Heart from 4 to 6 November in Münster. 75 participants took advantage of this special format to learn specifically about current developments in controlled whole-body reperfusion.

In this context, Dirk Buchwald from the Bergmannsheil University Hospital reported on his experiences with the CARL System in everyday clinical practice under the title “CARL under resuscitation — the details make the difference”. Maik Foltan from the University Hospital Regensburg explained the application of CARL with special reference to the fixation of the cannulae by presenting case studies. And Jan-Steffen Pooth from the Medical Center – University of Freiburg presented the latest clinical results of the ongoing multi-centre study on CARL to the symposium participants.

On the first day of the conference in Münster, there was also a hands-on workshop, where Christian Scherer, head of the CARL Support team, demonstrated the implementation of the complete CARL System in case of resuscitation.

CARL was already represented for the second time at the International Annual Meeting of the German Society for Cardiovascular Engineering (DGfK) and the Joint Focus Meeting Heart of the German Society for Thoracic, Cardiac and Vascular Surgery (DGTHG). This time, a total of 500 congress visitors had the opportunity to get to know the Resuscitec GmbH product line at a booth in the Messe und Congress Centrum, Halle Münsterland.

Thomas Kraft, CEO of the Resuscitec GmbH, in an exchange about the CARL System with a perfusionist from Spain.

This year’s motto of the conference was “Team Perfusion 2022 – stay connected”. According to the conference presidents Thomas Dreizler and Stephan Ensminger, this title recruited from the experience that the connection between cardiovascular engineering, cardiac surgery and anaesthesia plays a central role in almost all aspects of multidisciplinary cooperation. The topic also concerns Resuscitec GmbH, because multidisciplinary cooperation between the individual departments is a decisive factor in the implementation of company-specific goals.


< Back